

डा. राजीव सिंह रघुवंशी  
सचिव-सह-वैज्ञानिक निदेशक

Dr. Rajeev Singh Raghuvanshi  
Secretary-cum-Scientific Director

F. No. T.11015/01/2020-AR&D

Date: 13<sup>th</sup> December, 2022

### Subject: Corrigendum to Amendment List 01 of IP 2022

This has reference to the issuance of Amendment List 01 to IP 2022 dated 28<sup>th</sup> November, 2022. It is brought to the notice of all concerned that amendment in the Anti Human Globulin (AHG) Serum on page 6 of the Amendment List 01 shall be read as:

| Type of Reagent     | Test<br>Red Blood Cells  | Potency   |
|---------------------|--|---|
| Anti Human Globulin | Sensitized O+ve (R <sub>1</sub> r or R <sub>1</sub> R <sub>2</sub> )-C3d<br>Sensitized O+ve (R <sub>1</sub> r or R <sub>0</sub> r)-IgG | <b>Anti C3d</b> 1: ≥4<br><b>Anti-IgG</b> 1: ≥32 |

  
(Dr. Rajeev Singh Raghuvanshi)  
Secretary-cum-Scientific Director